Grants and Contracts Details
Description
Ovarian cancer is a deadly disease. More than 20,000 women will be diagnosed with and approximately
14,000 will die of ovarian cancer in 2022. In the front-line setting, women are treated with a platinum
compound (cisplatin and its analogues) and paclitaxel, and although up to 80% will respond initially, the
majority recur and present with platinum-resistant disease. There is currently no effective treatment for
platinum-resistant ovarian cancer. To overcome resistance and address this unmet medical, we have
developed novel gold compounds as a treatment strategy for women with platinum-resistant ovarian cancer.
These gold compounds are tuned for mitochondrial localization, demonstrated to disrupt mitochondrial
structure in cancer cells, decrease mitochondrial biogenesis, are cancer selective, and have significant
anticancer activity across multiple cancer cell lines. Gold compounds also decrease mitochondrial structure
proteins. We hypothesize that these compounds directly and selectively interact with mitochondrial
membranes resulting in reduced structural proteins (DRP1) and will adversely impact cancer cell
energy pathways. The overall goal of our research is to evaluate the ability of mitochondrial targeting gold-
based compounds to overcome platinum resistant ovarian cancer. In this proposal we will evaluate the activity
of gold compounds on cell proliferation and cytotoxicity in ovarian cancer organoids (Aim 1). We will then
evaluate the most active gold compounds in platinum sensitive and resistant ovarian xenografts (Aim 2). In
both aims we will assess mitochondrial bioenergetics and function through mitochondrial respiration and stable
isotope resolved (SIRM) metabolomics studies. Taken together, this application is highly innovative,
evaluating a novel class of compounds in ovarian cancer, clinical relevant, using patient derived organoids and
mechanistically important, providing key insights into the action of gold compounds on cellular metabolism.
Status | Finished |
---|---|
Effective start/end date | 6/1/22 → 6/30/24 |
Funding
- Markey Cancer Center Foundation: $50,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.